Guo Rui-xia, Zhang Rui-fang, Wang Xin-yan, Shi Hui-rong, Qiao Yu-huan
Department of Obstetrics and Gynecology, First Affiliated Hospital, Zhengzhou University, China.
Zhonghua Fu Chan Ke Za Zhi. 2011 Jun;46(6):446-52.
To investigate the effects of signal pathway inhibitors PD98059 and LY294002 on cell proliferation, apoptosis, expressions of phosphorylated extracellular signal-regulared kinase (p-ERK) and phosphorylated protein kinase B (p-Akt) in endometrial carcinoma xenografts.
Human endometrial carcinoma Ishikawa cells were cultured in vitro. The effects of PD98059 and LY294002 on proliferation, apoptosis, and cell cycle distribution of endometrial cancer cells were detected by monotetrazolium (MTT) assay and fluorescence-activated cell sorting technique. The models of xenografted tumor were established by the subcutaneous inoculation in 24 nude mice, and then they were randomly divided into 4 groups (n = 6), normal saline group, PD98059 group (PD group), LY294002 group (LY group) or PD98059 + LY294002 group (PD + LY group) by intraperitoneal injections, respectively. The anti-tumor efficacy was evaluated by measuring tumor volume and tumor growth status. The histopathological change of tumor specimens was observed using HE staining and terminal deoxynucleotidyl transferase-mediated dUTP-digoxigen in nick and labeling method (TUNEL) testing and the expression levels of p-ERK and p-Akt were detected by immunohistochemistry method.
(1) The proliferation of Ishikawa cells were suppressed after treated by PD98059 and(or) Y294002, in which A(570) values of cells decreased showing both time-dependent and concentration-dependent manner (LY294002: F(group) = 9.801, P = 0.002; F(time) = 10.398, P = 0.001. PD98059: F(group) = 8.213, P = 0.015; F(time) = 6.839, P = 0.036). Cell cycle distribution analysis revealed that percentage of Ishikawa cells at G(0)/G(1) phase (F(time) = 35.049, P = 0.004; F(group) = 32.024, P < 0.01) increased and percentage of S phase cells (F(time) = 7.789, P = 0.049; F(group) = 30.132, P < 0.01) decreased significantly. The percentage of apoptotic cells increased significantly among PD group, LY group and PD + LY group, in which there were significant difference [(63.3 ± 0.5)% vs (30.7 ± 20.1)% vs (40.8 ± 1.3)%; F = 621.059, P < 0.01]. (2) Compared with the control group, the increasing of transplanting tumor volume in the treated groups were obviously (F = 23.545, P < 0.01), and the inhibited rate of the tumor was higher in PD + LY group than that in PD group or LY group [(68 ± 9)% vs (32 ± 16)% or (38 ± 17)%; F = 10.283, P < 0.05]. (3) HE staining shown that there were different degrees of necrosis for endometrial carcinoma cell in different groups. The apoptosis of tumor cells were significantly increased in treated groups by TUNEL testing [(13.7 ± 1.5)%, (14.1 ± 1.2)%, (29.0 ± 1.8)%; F = 320.344, P < 0.01]. Immunohistochemistry results demonstrated that the expressions of p-ERK and p-Akt in treated groups were lower than that in control group, of which LY + PD group was the lowest one.
The signal pathway inhibitors PD98059 and LY294002 could inhibit the growth of human endometrial carcinoma in vivo and in vitro, in which may induce cell apoptosis.
探讨信号通路抑制剂PD98059和LY294002对子宫内膜癌移植瘤细胞增殖、凋亡、磷酸化细胞外信号调节激酶(p-ERK)及磷酸化蛋白激酶B(p-Akt)表达的影响。
体外培养人子宫内膜癌Ishikawa细胞,采用噻唑蓝(MTT)法和荧光激活细胞分选技术检测PD98059和LY294002对子宫内膜癌细胞增殖、凋亡及细胞周期分布的影响。将24只裸鼠皮下接种建立移植瘤模型,然后通过腹腔注射随机分为4组(n = 6),分别为生理盐水组、PD98059组(PD组)、LY294002组(LY组)或PD98059 + LY294002组(PD + LY组)。通过测量肿瘤体积和肿瘤生长状态评估抗肿瘤疗效。采用苏木精-伊红(HE)染色观察肿瘤标本的组织病理学变化,采用脱氧核糖核苷酸末端转移酶介导的缺口末端标记法(TUNEL)检测细胞凋亡情况,采用免疫组织化学方法检测p-ERK和p-Akt的表达水平。
(1)PD98059和(或)LY294002处理后Ishikawa细胞增殖受到抑制,细胞A(570)值降低,呈时间和浓度依赖性(LY294002:F(组)= 9.801,P = 0.002;F(时间)= 10.398,P = 0.001。PD98059:F(组)= 8.213,P = 0.015;F(时间)= 6.839,P = 0.036)。细胞周期分布分析显示,Ishikawa细胞在G(0)/G(1)期的百分比(F(时间)= 35.049,P = 0.004;F(组)= 32.024,P < 0.01)增加,S期细胞百分比(F(时间)= 7.789,P = 0.049;F(组)= 30.132,P < 0.01)显著降低。PD组、LY组和PD + LY组凋亡细胞百分比显著增加,差异有统计学意义[(63.3 ± 0.5)% vs (30.7 ± 20.1)% vs (40.8 ± 1.3)%;F = 621.059,P < 0.01]。(2)与对照组相比,各治疗组移植瘤体积增长明显(F = 23.545,P < 0.01),且PD + LY组肿瘤抑制率高于PD组或LY组[(68 ± 9)% vs (32 ± 16)%或(38 ± 17)%;F = 10.283,P < 0.05]。(3)HE染色显示不同组子宫内膜癌细胞有不同程度坏死。TUNEL检测显示治疗组肿瘤细胞凋亡显著增加[(13.7 ± 1.5)%,(14.1 ± 1.2)%,(29.0 ± 1.8)%;F = 320.344,P < 0.01]。免疫组织化学结果显示,各治疗组p-ERK和p-Akt表达低于对照组,其中LY + PD组最低。
信号通路抑制剂PD98059和LY294002可在体内外抑制人子宫内膜癌生长,可能诱导细胞凋亡。